Evaluating intraocular pressure-lowering solutions for the treatment of open-angle glaucoma: comparison between bimatoprost 0.03% and bimatoprost 0.01% — an observational switch study

References

• QuigleyHABromanATThe number of people with glaucoma worldwide in 2010 and 2020Br J Ophthalmol200690326226716488940
   PubMed Web of Science ®Google Scholar
• LindseyJDKashiwagiKKashiwagiFWeinrebRNProstaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitroInvest Ophthalmol Vis Sci19973811221422239344344
   PubMed Web of Science ®Google Scholar
• WeinrebRNLindseyJDMetalloproteinase gene transcription in human ciliary muscle cells with latanoprostInvest Ophthalmol Vis Sci200243371672211867589
   PubMed Web of Science ®Google Scholar
• WanZWoodwardDFCornellCLBimatoprost, prostamide activity, and conventional drainageInvest Ophthalmol Vis Sci20074894107411517724194
   PubMed Web of Science ®Google Scholar
• BrubakerRFMechanism of action of bimatoprost (Lumigan)Surv Ophthalmol200145Suppl 4S347S35111434937
   PubMed Web of Science ®Google Scholar
• WaltersTRDuBinerHBCarpenterSPKhanBVanDenburghAMBimatoprost Circadian IOP Study Group 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trialSurv Ophthalmol200449Suppl 1S26S3515016559
   PubMed Web of Science ®Google Scholar
• NoeckerRSDirksMSChoplinNTBernsteinPBatoosinghALWhitcupSMBimatoprost/Latanoprost Study GroupA six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucomaAm J Ophthalmol20031351556312504698
   PubMed Web of Science ®Google Scholar
• GandolfiSSimmonsSTSturmRChenKVanDenburghAMBimatoprost Study Group 3Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertensionAdv Ther200118311012111571823
   PubMed Web of Science ®Google Scholar
• ParrishRKPalmbergPSheuWPGroupXLTSA comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter studyAm J Ophthalmol2003135568870312719078
   PubMed Web of Science ®Google Scholar
• MartinezASanchezMIntraocular pressure lowering effect of dorzolamide/timolol fixed combination in patients with glaucoma who were unresponsive to prostaglandin analogs/prostamidesCurr Med Res Opin200723359559917355740
   PubMed Web of Science ®Google Scholar
• WilliamsRDEfficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprostAdv Ther200219627528112665048
   PubMed Web of Science ®Google Scholar
• GandolfiSACiminoLEffect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprostOphthalmology2003110360961412623831
   PubMed Web of Science ®Google Scholar
• NakamuraTYamadaMTeshimaMElectrophysiological characterization of tight junctional pathway of rabbit cornea treated with ophthalmic ingredientsBiol Pharm Bull200730122360236418057726
   PubMed Web of Science ®Google Scholar
• KatzLJCohenJSBatoosinghALFelixCShuVSchiffmanRMTwelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertensionAm J Ophthalmol20101494661671.e120346780
   PubMed Web of Science ®Google Scholar
• CampbellJHSchwartzGLabountyBKowalskiJPatelVDComparison of adherence and persistence with bimatoprost 0.01% versus bimatoprost 0.03% topical ophthalmic solutionsCurr Med Res Opin20132991201120923865686
   PubMed Web of Science ®Google Scholar
• FigusMNardiMPiaggiPBimatoprost 0.01% versus bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patientsEye (Lond)201428442242924434659
   PubMed Web of Science ®Google Scholar
• MyersJSVoldSZamanFWilliamsJMHollanderDABimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trialsClin Ophthalmol2014864365224707169
   PubMedGoogle Scholar
• OgundeleABLiGEllisJJImpact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbitsClin Ophthalmol20104778020186281
   PubMedGoogle Scholar
• WongWBPatelVDKowalskiJWSchwartzGAn adherence based cost-consequence model comparing bimatoprost 0.01% to bimatoprost 0.03%Curr Med Res Opin20132991191120023865609
   PubMed Web of Science ®Google Scholar
• KookMSSimonyiSSohnYHKimCYParkKHBimatoprost 0.01% for previously treated patients with open-angle glaucoma or ocular hypertension in the Korean clinical settingJpn J Ophthalmol201559532533426202440
   PubMed Web of Science ®Google Scholar
• ParkKHSimonyiSKimCYSohnYHKookMSBimatoprost 0.01% in treatment-naive patients with open-angle glaucoma or ocular hypertension: an observational study in the Korean clinical settingBMC Ophthalmol20141416025519810
   PubMed Web of Science ®Google Scholar
• DuBinerHBHubatschDALate-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trialBMC Ophthalmol20141415125432143
   PubMed Web of Science ®Google Scholar
• CrichtonACNixonDRSimonyiSAn observational study of bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: the Canadian Lumigan(®) RC Early Analysis Review (CLEAR) trialClin Ophthalmol201481031103824920879
   PubMedGoogle Scholar
• CampbellJHSchwartzGFLaBountyBKowalskiJWPatelVDPatient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutionsClin Ophthalmol2014892793524868144
   PubMedGoogle Scholar
• NixonDRA randomized, prospective study of bimatoprost 0.01% or travoprost/timolol in patients previously treated with latanoprost and timolol to reduce intraocular pressureJ Ocul Pharmacol Ther2013291087688124070367
   PubMed Web of Science ®Google Scholar
• NixonDRSimonyiSBhogalMAn observational study of bimatoprost 0.01% in treatment-naive patients with primary open angle glaucoma or ocular hypertension: the CLEAR trialClin Ophthalmol201262097210323269858
   PubMedGoogle Scholar
• PfennigsdorfSRamezOvon KistowskiGMulticenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertensionClin Ophthalmol2012673974622654501
   PubMedGoogle Scholar
• McCarneyRWarnerJIliffeSvan HaselenRGriffinMFisherPThe Hawthorne Effect: a randomised, controlled trialBMC Med Res Methodol200773017608932
   PubMed Web of Science ®Google Scholar
• GuptaVSrinivasanGSharmaAKapoorKSSihotaRComparative evaluation of bimatoprost monotherapy in primary chronic angle closure and primary open angle glaucoma eyes: a three-year studyJ Ocul Pharmacol Ther200723435135817803433
   PubMed Web of Science ®Google Scholar
• SontySDonthamsettiVVangipuramGAhmadALong-term IOP lowering with bimatoprost in open-angle glaucoma patients poorly responsive to latanoprostJ Ocul Pharmacol Ther200824551752018800869
   PubMed Web of Science ®Google Scholar